VBL Therapeutics is focused on developing targeted therapies for immune-inflammatory diseases, with a particular emphasis on their lead candidate, VB-601. This investigational monoclonal antibody utilizes a proprietary Monocyte Targeting Technology (MTT) designed to specifically limit chronic inflammation by targeting monocytes, which are critical drivers of the inflammatory process. The technology is based on the identification of a novel target protein, MOSPD2, which is selectively expressed on the surface of monocytes and regulates their migration to inflamed tissues. By binding to the MOSPD2 receptor, VB-601 effectively prevents monocytes from reaching areas of inflammation, offering a unique approach compared to existing anti-inflammatory agents that primarily target T and B lymphocytes.

VBL's MTT represents a differentiated strategy in the treatment of various immune-inflammatory diseases, including multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease. Unlike traditional therapies that often face challenges due to the redundancy of chemoattractants and receptors, VB-601 aims to immobilize monocytes in the perivascular space, thereby reducing their contribution to chronic inflammation. The company plans to initiate a first-in-human study of VB-601, highlighting its potential utility across a broad spectrum of inflammatory conditions, both prevalent and rare.

Israel

VBL Therapeutics (Nasdaq: VBLT) is developing targeted therapies for immune-inflammatory diseases. VBL’s lead immunology product candidate VB-601 is a targeted antibody for immune-inflammatory applications expected to enter Phase 1 this year that has shown disease-modifying activity across multiple preclinical models including multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease.

VBL Therapeutics

Company Details